Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05635162
Other study ID # UCL 146660
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 17, 2024
Est. completion date October 2028

Study information

Verified date June 2024
Source University College, London
Contact ZEBRA Trial Manager
Phone (+44) (0)2076799860
Email ctc.zebra@ucl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase II, multicentre, randomised, open-label study to assess the benefit of early intervention with fixed duration, time-limited zanubrutinib-rituximab in indolent mantle cell lymphoma (MCL)


Description:

This is a phase II, multicentre, randomised open label study to assess the safety and efficacy of zanubrutinib in combination with rituximab for previously untreated indolent MCL patients. 50 patients will be recruited from 15 UK centres over 30 months. Enrolled patients will be randomised (1:1) to ongoing observation (control arm; arm A) or fixed-duration zanubrutinib-rituximab (experimental arm; arm B). Patients will discontinue zanubrutinib-rituximab after 6 cycles of therapy or sooner in the advent of unacceptable toxicity or any other reason. All patients will be followed up for a minimum of 2 years after randomisation. Patients in arm B who develop disease progression and require further therapy after the initial time-limited Zanu-R will receive standard of care therapy according to front line treatment available at that time.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 2028
Est. primary completion date October 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. 18 years of age or over. 2. Life expectancy = 6 months. 3. Pathologically confirmed MCL, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1, D2 or D3. 4. Stage II-IV MCL measurable by CT imaging or by white cell count (WCC)/BM infiltration. 5. 'Indolent' MCL, defined as 1 or more of the following: - Observation with no treatment for a minimum of 6 months after the initial diagnosis - Leukaemic non-nodal variant (lymphocytosis/splenomegaly only without nodal involvement) - Low tumour volume (largest lymph node = 3cm in maximal diameter), proliferation fraction (Ki67 or equivalent) =30% and classical morphology (non-blastoid/pleomorphic) 6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. 7. Absolute neutrophil count =1.0 x 109/L and platelets =75 x 109/L independent of growth factor support. 8. AST and/or ALT =3 x upper limit of normal (ULN). 9. Total Bilirubin =1.5 x ULN unless due to Gilberts syndrome or of non-hepatic origin unless directly attributable to the patient's MCL. 10. Calculated creatinine clearance =30 mL/min. Glomerular filtration rate (GFR) =30 mL/min directly measured with 24 hour urine collection, or creatinine clearance calculated according to the modified formula of Cockcroft and Gault (for men: GFR ˜ ((140 - age) x bodyweight)/ (72 x creatinine), for women x 0, 85). 11. Able to give voluntary written informed consent. 12. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty. 13. Negative serum or urine pregnancy test for women of childbearing potential (WOCBP). 14. Willing to comply with the contraceptive requirements of the trial. Exclusion Criteria: 1. Any prior therapy for MCL, including prior radiotherapy. 2. Central nervous system (CNS) involvement of MCL. 3. Uncontrolled infection with HIV or any uncontrolled active systemic infection (e.g., bacterial, viral or fungal). Patients with well-controlled HIV status (undetectable viral load) will not be excluded. 4. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HB core) positive and who are surface antigen (HBsAg) negative will need to have a negative polymerase chain reaction (PCR) test. Those who are hepatitis B HbsAg positive or hepatitis B PCR positive will be excluded. Those who are hepatitis C antibody and PCR positive will be excluded (those who are hepatitis C antibody positive and PCR negative will not be excluded). 5. No progression requiring treatment since initial diagnosis. 6. Vaccinated with live vaccines (not including messenger ribonucleic acid (mRNA), viral vector or other non-live COVID19 vaccines) within four weeks prior to randomisation. 7. Major surgical procedure within 28 days prior to randomisation. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug. 8. Prior malignancy (or any other malignancy requiring active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, localised prostate cancer or other cancer from which the subject has been disease free for = 2 years or which will not limit survival to < 5 years. 9. Requirement for moderate or strong CYP3A inducers. Moderate and strong CYP3A inhibitors are allowed although these should be switched to agents causing less CYP3A inhibition where possible. 10. Requirement for vitamin K antagonists (alternative anticoagulation is allowed (e.g. DOACs), but patients must be properly informed about the potential risk of bleeding alongside zanubrutinib). Requires ongoing treatment with warfarin or warfarin derivatives 11. Active bleeding or history of bleeding diathesis (e.g. haemophilia or von Willebrand disease) or history of spontaneous bleeding requiring blood transfusion or other medical intervention. 12. Clinically significant cardiovascular disease such as uncontrolled arrhythmias, or history of ventricular tachycardia, ventricular fibrillation, torsades de points or myocardial infarction within 6 months of randomisation, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association (NYHA) Functional Classification, or corrected QT interval (QTc) > 480 msec, second-degree atrioventricular block Type II, third-degree atrioventricular block at randomisation, unstable angina within 3 months prior to randomisation. 13. History of stroke or intracranial haemorrhage within 6 months prior to randomisation. 14. Any other severe medical or psychiatric illness that in the opinion of the investigator would interfere with participation in this clinical study. 15. Malabsorption syndrome, unable to swallow capsules, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass. 16. Women who are pregnant or breastfeeding. 17. Male participants with female partners of childbearing potential who are unwilling to use appropriate contraception methods. 18. Concurrent treatment with another investigational agent. 19. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, known sensitivity or allergy to murine products. 20. Known hypersensitivity to any active substance or to any of the excipients of one of the drugs used in the trial. 21. Severe or debilitating pulmonary disease. 22. Underlying medical conditions that, in the investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs 23. Concurrent participation in another therapeutic clinical trial. 24. Active and/or ongoing autoimmune anaemia and/or autoimmune thrombocytopenia (eg. idiopathic thrombocytopenia purpura).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Zanubrutinib
Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
Rituximab
Rituximab 375 mg/m2 intravenous (IV)* on day 1 (+/-3 days) of each 28-day cycle

Locations

Country Name City State
United Kingdom University College London Hospital London
United Kingdom Christie Hospital Manchester
United Kingdom Churchill Hospital Oxford

Sponsors (2)

Lead Sponsor Collaborator
University College, London BeiGene

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Event free survival To determine the effect of fixed-duration Zanu-R on Event-free survival (EFS) compared to active observation From date of randomisation until whichever comes first: occurrence of active disease, new MCL treatment or death (any cause) up to 60 months
Secondary Progression free survival To determine the effect of fixed-duration Zanu-R on Progression free survival (PFS) compared to active observation Randomisation until disease progression up to 60 months
Secondary Overall survival To determine the effect of fixed-duration Zanu-R on overall survival (OS) compared to active observation Randomisation until date of death up to 60 months
Secondary Time to next treatment To determine the effect of fixed-duration Zanu-R on time to next treatment (TTNT) compared to active observation Randomisation until date of initiation of subsequent treatment up to 60 months
Secondary Time to second progression To determine the effect of fixed-duration Zanu-R on time to second progression compared to active observation From date of randomisation or date of first progression until date of second progression or death from any cause up to 60 months
Secondary Overall response rate to Zanu-R To determine the effect of fixed-duration Zanu-R on overall response rate (ORR) at the end of 6 cycles of treatment From start of treatment until 24 weeks post administration of Zanu-R
Secondary Overall response rate to re-treatment with covalent BTKi To determine the ORR to re-treatment with covalent BTKi in experimental arm From the start of further treatment with a BTKi through to study completion, an average of 60 months
Secondary Safety and Toxicity To assess the worst grade of each adverse event for each patient. Grades 1-2 and grades 3-5 will be compared between the arms From informed consent until 28 weeks post randomisation
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05976763 - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Phase 3
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Recruiting NCT05471843 - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05076097 - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT03891355 - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01665768 - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Phase 2
Completed NCT01437709 - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Phase 2
Completed NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Phase 1/Phase 2
Completed NCT00921414 - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Phase 3
Withdrawn NCT00541424 - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma N/A
Completed NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Phase 3
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Completed NCT03295240 - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Early Phase 1